RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Beijing’s BeiGene in-licensed a conditionally activated inhibitor of CTLA-4 from BioAtla of San Diego in a $269 million agreement. The two companies will test BA3071 (CAB-CTLA-4) as a monotherapy and in combination with BeiGene’s PD-1 candidate, tislelizumab. BioAtla will receive $20 million up front and is eligible for undisclosed early clinical milestones, plus $249 million in subsequent milestones. BeiGene will own a co-exclusive license with BioAtla to develop and manufacture the candidate, along with an exclusive global commercialization license.
Source: China Biotoday
